Tenon Medical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Steven Foster

Algemeen directeur

US$487.6k

Totale compensatie

Percentage CEO-salaris	82.0%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

We're A Little Worried About Tenon Medical's (NASDAQ:TNON) Cash Burn Rate

Nov 29

Is Tenon Medical (NASDAQ:TNON) In A Good Position To Invest In Growth?

Aug 15

Analyse CEO-vergoeding

Hoe is Steven Foster's beloning veranderd ten opzichte van Tenon Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$488k	US$400k	-US$16m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$300k	-US$19m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$460k	US$175k	-US$7m

Compensatie versus markt: De totale vergoeding ($USD 487.60K ) Steven } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).

Compensatie versus inkomsten: De vergoeding van Steven is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Steven Foster (56 yo)

3.8yrs

Tenure

US$487,600

Compensatie

Mr. Steven M. Foster serves as Director of HAPPE Spine, LLC since March 2022. He serves as Chief Executive Officer, President of Tenon Medical, Inc. and serves as its Director since 2021 and served as its...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Ferrari	Founder & Executive Chairman	12.8yrs	US$247.50k	1.02% $ 19.9k
Steven Foster	CEO, President & Director	3.8yrs	US$487.60k	0.60% $ 11.7k
Richard Ginn	Founder	12.8yrs	US$350.23k	2.03% $ 39.5k
Robert Weigle	Independent Director	2.6yrs	US$67.50k	0.032% $ 613.1
Stephen Hochschuler	Independent Director	2.6yrs	US$45.00k	0.16% $ 3.0k
Kristine Jacques	Independent Director	less than a year	geen gegevens	geen gegevens
Ivan Howard	Independent Director	2.8yrs	US$60.00k	0.032% $ 613.1

2.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TNON wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Tenon Medical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Tenon Medical, Inc. Appoints Kevin Williamson as Chief Financial Officer

Tenon Medical, Inc., Annual General Meeting, Jul 23, 2024

Tenon Medical, Inc. Appoints Kristine Jacques as Independent Member of the Board of Directors

Tenon Medical, Inc. Announces Resignation of Frank Fischer as Member of Board of Directors, Audit Committee and Chairman of the Compensation Committee

Tenon Medical, Inc., Annual General Meeting, Sep 13, 2023

Founder recently sold US$82k worth of stock

Recent updates

Tenon Medical, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Tenon Medical Regains Full Compliance with Nasdaq Continued Listing Requirements

Tenon Medical Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement

Tenon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.499971 million.

Consensus EPS estimates upgraded to US$19.35 loss

Tenon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $4.500088 million.

Tenon Medical Receives Non-Compliance Letter Regarding Minimum Float Requirement

Tenon Medical, Inc. Appoints Kevin Williamson as Chief Financial Officer

Consensus EPS estimates upgraded to US$3.73 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations

Tenon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Tenon Medical, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Tenon Medical, Inc., Annual General Meeting, Jul 23, 2024

Consensus EPS estimates fall by 18%, revenue upgraded

Consensus EPS estimates fall by 11%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Tenon Medical Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5550(a)(2)

Tenon Medical, Inc. to Report Q1, 2024 Results on May 14, 2024

Tenon Medical, Inc. Appoints Kristine Jacques as Independent Member of the Board of Directors

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Tenon Medical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Tenon Medical Receives Non-Compliance Notice From Nasdaq

Tenon Medical, Inc. Announces Resignation of Frank Fischer as Member of Board of Directors, Audit Committee and Chairman of the Compensation Committee

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 12%, EPS upgraded

Tenon Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Tenon Medical(R) Announces First Patients Treated with New Jib Instrument Kit for Catamaran(R) Si Joint Fusion System

Tenon Medical, Inc. announced that it has received $0.286835 million in funding from Lincoln Park Capital, LLC

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Tenon Medical, Inc., Annual General Meeting, Sep 13, 2023

Tenon Medical, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Tenon Medical Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price

New major risk - Shareholder dilution

Tenon Medical, Inc. has completed a Composite Units Offering in the amount of $5.6 million.

New major risk - Share price stability

New major risk - Market cap size

Founder recently sold US$82k worth of stock

Tenon Medical Receives A Written Notice from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released

We're A Little Worried About Tenon Medical's (NASDAQ:TNON) Cash Burn Rate

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings released

Tenon Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Tenon Medical, Inc.'s Catamaran SI Joint Fusion System Receives Institutional Review Board Approval for Two Strategic Post Market Studies

Is Tenon Medical (NASDAQ:TNON) In A Good Position To Invest In Growth?

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$2.01 loss in 2Q 2021)

Tenon Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$2.38 loss per share (vs US$0.24 loss in 1Q 2021)

High number of new directors

Tenon Medical, Inc. has completed an IPO in the amount of $16 million.

Less than half of directors are independent